slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 75,511-75,540
Pages 3,225
Rows per page 30
Component
75,511-75,540 of 96,741
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
210
The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
213
The slide uses a 'claim-refutation' structure to dismantle the target company's product differentiation narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
217
Uses expert quotes to debunk the necessity of the company's proprietary drug formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
218
Uses FDA label excerpts to highlight the contradiction between the drug's design and its actual usage/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
219
The slide uses Q&A transcripts to highlight internal knowledge of safety risks and potential for generic substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
221
The slide uses a Q&A transcript format to build a case against the drug's physical formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
222
Uses a combination of product imagery and user-generated content (Facebook post) to critique the competitor's dosing complexity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
225
The slide uses direct quotes from an expert consultation to undermine the credibility of the drug's approval and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
226
The slide uses direct quotes from an ex-employee to build a case of corporate misconduct regarding clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
227
The slide uses a combination of a summary paragraph and a direct verbatim quote with highlighted sections.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
228
The slide uses a Q&A transcript format to highlight the alleged suppression of negative clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
229
The slide uses a Q&A format to highlight internal concerns regarding trial integrity and the potential for participant bias due to unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
230
The slide uses highlighted text to emphasize key criticisms (soft endpoints, cherry-picking, safety signals).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
231
The slide uses a Q&A transcript format to highlight potential safety data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
232
The slide uses a Q&A format to highlight potential corporate malfeasance regarding safety data reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
233
The slide uses a Q&A transcript format to validate the activist's thesis regarding data manipulation and competitive threat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
234
The slide uses a long, narrative-style headline that summarizes the ex-employee's critique, followed by a highlighted block quote.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
235
The slide uses Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
237
The slide uses a Q&A format to frame the contradiction between weight loss goals and diabetes risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit